vs

Side-by-side financial comparison of FIRST NATIONAL CORP (FXNC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $24.0M, roughly 1.6× FIRST NATIONAL CORP). On growth, FIRST NATIONAL CORP posted the faster year-over-year revenue change (-3.4% vs -57.1%). Over the past eight quarters, FIRST NATIONAL CORP's revenue compounded faster (26.8% CAGR vs -46.5%).

VA Tech Wabag Ltd. is an Indian multinational company focussed on desalination and water treatment for municipal and industrial users. Founded in Breslau in 1924, the company is headquartered in Chennai.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

FXNC vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.6× larger
ORGO
$37.2M
$24.0M
FXNC
Growing faster (revenue YoY)
FXNC
FXNC
+53.7% gap
FXNC
-3.4%
-57.1%
ORGO
Faster 2-yr revenue CAGR
FXNC
FXNC
Annualised
FXNC
26.8%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FXNC
FXNC
ORGO
ORGO
Revenue
$24.0M
$37.2M
Net Profit
$5.5M
Gross Margin
30.8%
Operating Margin
28.8%
-185.1%
Net Margin
23.0%
Revenue YoY
-3.4%
-57.1%
Net Profit YoY
689.9%
EPS (diluted)
$0.60

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FXNC
FXNC
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$24.0M
$225.6M
Q3 25
$22.8M
$150.9M
Q2 25
$22.4M
$101.0M
Q1 25
$21.1M
$86.7M
Q4 24
$24.8M
$126.7M
Q3 24
$15.0M
$115.2M
Q2 24
$14.2M
$130.2M
Net Profit
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
$5.5M
$43.7M
Q3 25
$5.5M
$21.6M
Q2 25
$5.1M
$-9.4M
Q1 25
$1.6M
$-18.8M
Q4 24
$-933.0K
$7.7M
Q3 24
$2.2M
$12.3M
Q2 24
$2.4M
$-17.0M
Gross Margin
FXNC
FXNC
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
FXNC
FXNC
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.8%
28.1%
Q3 25
29.9%
13.7%
Q2 25
28.2%
-12.5%
Q1 25
9.0%
-30.9%
Q4 24
-29.0%
8.1%
Q3 24
18.7%
5.4%
Q2 24
22.0%
-10.7%
Net Margin
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
23.0%
19.4%
Q3 25
24.3%
14.3%
Q2 25
22.5%
-9.3%
Q1 25
7.6%
-21.7%
Q4 24
-14.4%
6.1%
Q3 24
15.0%
10.7%
Q2 24
17.2%
-13.1%
EPS (diluted)
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
$0.60
$0.31
Q3 25
$0.62
$0.11
Q2 25
$0.56
$-0.10
Q1 25
$0.18
$-0.17
Q4 24
$-0.26
$0.05
Q3 24
$0.36
$0.09
Q2 24
$0.39
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FXNC
FXNC
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$160.9M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$186.2M
Total Assets
$2.0B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FXNC
FXNC
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$160.9M
$93.7M
Q3 25
$189.3M
$63.7M
Q2 25
$194.3M
$73.1M
Q1 25
$206.0M
$110.0M
Q4 24
$162.9M
$135.6M
Q3 24
$126.5M
$94.3M
Q2 24
$135.6M
$89.9M
Total Debt
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
$186.2M
$300.1M
Q3 25
$181.2M
$255.1M
Q2 25
$173.5M
$233.2M
Q1 25
$168.7M
$242.9M
Q4 24
$166.5M
$262.9M
Q3 24
$125.1M
$278.5M
Q2 24
$119.9M
$263.5M
Total Assets
FXNC
FXNC
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$2.0B
$598.7M
Q3 25
$2.0B
$509.8M
Q2 25
$2.0B
$461.1M
Q1 25
$2.0B
$467.4M
Q4 24
$2.0B
$497.9M
Q3 24
$1.5B
$446.3M
Q2 24
$1.5B
$443.2M
Debt / Equity
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FXNC
FXNC
ORGO
ORGO
Operating Cash FlowLast quarter
$25.1M
Free Cash FlowOCF − Capex
$20.9M
FCF MarginFCF / Revenue
87.3%
Capex IntensityCapex / Revenue
17.4%
Cash ConversionOCF / Net Profit
4.56×
TTM Free Cash FlowTrailing 4 quarters
$34.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
$25.1M
$39.4M
Q3 25
$8.4M
$3.1M
Q2 25
$4.7M
$-32.9M
Q1 25
$3.5M
$-19.9M
Q4 24
$-22.2M
$10.9M
Q3 24
$6.1M
$8.7M
Q2 24
$3.6M
$4.7M
Free Cash Flow
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
$20.9M
$34.8M
Q3 25
$6.8M
$844.0K
Q2 25
$4.1M
$-36.5M
Q1 25
$3.0M
$-23.6M
Q4 24
$-25.5M
$7.6M
Q3 24
$4.9M
$6.1M
Q2 24
$3.0M
$2.9M
FCF Margin
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
87.3%
15.4%
Q3 25
30.0%
0.6%
Q2 25
18.3%
-36.1%
Q1 25
14.5%
-27.2%
Q4 24
-102.8%
6.0%
Q3 24
33.0%
5.3%
Q2 24
21.0%
2.2%
Capex Intensity
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
17.4%
2.1%
Q3 25
7.0%
1.5%
Q2 25
2.6%
3.6%
Q1 25
2.3%
4.2%
Q4 24
13.3%
2.7%
Q3 24
8.1%
2.2%
Q2 24
4.6%
1.4%
Cash Conversion
FXNC
FXNC
ORGO
ORGO
Q1 26
Q4 25
4.56×
0.90×
Q3 25
1.52×
0.14×
Q2 25
0.93×
Q1 25
2.21×
Q4 24
1.43×
Q3 24
2.73×
0.71×
Q2 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons